Upsher-Smith Kicks Off 2020 With Three Generic Product Launches
MAPLE GROVE, Minn., Feb. 19, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its generic portfolio with the recent launch of three new products: Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP, and Clonidine Hydrochloride Extended-Release Tablets. The market for these three products had combined U.S. sales of nearly $102.5 million for the twelve months ending December 2019, according to IQVIA.
The Company has committed itself to aggressively growing the number of generic programs in its portfolio. Over the next few years, through both internal research and development and external partnerships, Upsher-Smith will substantially expand its pipeline. This effort is being supported by an investment in infrastructure with the construction of a state-of-the-art, efficient, high-quality manufacturing facility at its Minnesota headquarters.
"We enter this new decade not only with our most aggressive growth plan in history, but also prepared to meet the challenging market conditions that lie ahead," said Rusty Field, President and CEO, Upsher-Smith. "We're proud of our strong reputation as a trusted partner in the generic marketplace and look forward to delivering even more affordable options to patients and healthcare professionals."
For questions about ordering Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP, and Clonidine Hydrochloride Extended-Release Tablets, please call Upsher-Smith at 1-800-654-2299. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
Boxed Warning for Fluvoxamine Maleate Tablets
Boxed Warning for Haloperidol Tablets, USP
Please refer to the full Prescribing Information, including Boxed Warnings for Fluvoxamine Maleate Tablets and Haloperidol Tablets, USP. Click here for full Prescribing Information for Clonidine Hydrochloride Extended-Release Tablets. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information for each product.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
As Upsher-Smith begins its second century in business, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit www.upsher-smith.com.
Do More Good is a trademark of Upsher-Smith Laboratories, LLC.
View original content to download multimedia:http://www.prnewswire.com/news-releases/upsher-smith-kicks-off-2020-with-three-generic-product-launches-301007427.html
SOURCE Upsher-Smith Laboratories, LLC